Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wedbush Initiates Coverage On Theseus Pharmaceuticals with Outperform Rating, Announces Price Target of $24

Wedbush analyst David Nierengarten initiates coverage on Theseus Pharmaceuticals (NASDAQ:THRX) with a Outperform rating and announces Price Target of $24.

byBenzinga Newsdesk

November 1, 2021

1 minute read

Wedbush analyst David Nierengarten initiates coverage on Theseus Pharmaceuticals (NASDAQ:THRX) with a Outperform rating and announces Price Target of $24.

Keybanc Maintains Overweight on Diamondback Energy, Raises Price Target to $102

By Benzinga Newsdesk

June 24, 4:46 AM

Keybanc maintains Diamondback Energy (NASDAQ:FANG) with a Overweight and raises the price target from $98 to $102.

FANG

Analyst Ratings

What 16 Analyst Ratings Have To Say About GoodRx Holdings

By Benzinga Insights

May 10, 3:15 PM

Analysts have provided the following ratings for GoodRx Holdings (NASDAQ:GDRX) within the last quarter:

GDRX

SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $108

By Benzinga Newsdesk

October 28, 12:21 PM

SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $104 to $108.

ALNY